Newsroom | 4720 results

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a negative opinion on the company’s marketing authorization application (MAA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) following re-examination of its original negative opinion adopted in June 2026. An eight-member ad hoc expert group (...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Reservoir today launched a personal cell preservation service that lets adults preserve their own immune cells through a standard blood draw. Reservoir is available today through partner clinics in San Francisco, Boston, Los Angeles, and New York City, with in-home appointments launching in select markets. Sign up at withreservoir.com to be matched with a nearby appointment or to receive updates when Reservoir comes to your city. To see Reservoir in action, go...

LAS VEGAS & PANAMA CITY--(BUSINESS WIRE)--Auragens, an international regenerative medicine and research institute, today announced that its research paper, "Molecular Dynamics Simulation of SOD3 and CXCR4 Proteins in Engineered Mesenchymal Stem Cells for Radiation Countermeasure Therapeutics," has been formally accepted for presentation at the 2027 American Institute of Aeronautics and Astronautics (AIAA) SciTech Forum, taking place January 11–15, 2027, in Orlando, Florida.The paper, authored by...

CLARKSBURG, Md.--(BUSINESS WIRE)--For the last 53 years, BrightFocus Foundation, a nonprofit dedicated to Alzheimer’s, macular degeneration, and glaucoma research, has been making an unconventional bet. What happens when you give promising and emerging scientists funding to pursue early‑stage, high‑risk research that could lead to major scientific advances and future competitive grants? According to an impact assessment commissioned by BrightFocus and conducted by the American Institute of Biol...

SAN DIEGO--(BUSINESS WIRE)--Please replace the release dated Sept. 29, 2026, with the following corrected version due to multiple revisions. The updated release reads: CYTOHUB CO-FOUNDER AITOR AGUIRRE NAMED TO LEAD CARDIAC TISSUE ENGINEERING AT NIH'S FIRST NATIONAL ORGANOID CENTER Dr. Aguirre will direct the Tissue Engineering Laboratories at NIH's $87 million Standardized Organoid Modeling Center at the Frederick National Laboratory for Cancer Research, bringing his pioneering expertise in hum...

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) and Magellan Stem Cells, a private Australian biotech and cell-therapy firm, announce their collaboration to support Magellan in the development and clinical advancement of its proprietary stem cell-based therapies and regenerative medicine solutions. The partnership will leverage Charles River’s specialized expertise in biologics quality control, current Good Manufacturing Practice (cGMP) viral and r...

CHICAGO--(BUSINESS WIRE)--Syntax Bio will present new research on its Cellgorithm™ cell-programming platform at the International Society for Stem Cell Research (ISSCR) iPSC 20th Anniversary Symposium, held Oct. 20-22 at the Kyoto International Conference Center in Kyoto, Japan. The research showed that Cellgorithm differentiated human induced pluripotent stem cells (iPSC) toward pancreatic beta cell states in four days. The study also identified genetic 'gridlocks' that stall cells at intermed...

BIRMINGHAM, Ala.--(BUSINESS WIRE)--Southern Research has been awarded an $8 million grant from the National Institutes of Health (NIH) to build the Translational Hub for Research, Innovation, Validation, and Excellence (THRIVE). THRIVE will be a national shared-use biomedical research facility focused on accelerating the development, validation, and adoption of new approach methodologies (NAMs), a broad range of laboratory, computational, and data-driven approaches designed to better reflect hu...

CAMBRIDGE, England--(BUSINESS WIRE)--Amphista Therapeutics Limited (‘Amphista’ or ‘the Company’), a leader in the discovery and development of non-cereblon / VHL targeted protein degradation (TPD) medicines, today announced dosing of the first patient in a Phase 1 trial for its lead candidate, AMX-883. Initiated following authorization from the U.S. Food and Drug Administration in June 2026, the BRAMLIE trial will investigate the safety, pharmacokinetics, and preliminary efficacy of AMX-883 mon...

OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American, Symbol: CCEL) (the “Company”, “Cryo-Cell”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal third quarter ended August 31, 2026. Financial Results Revenue Consolidated revenues for the third quarter of fiscal 2026 were $7.82 million compared to $7.83 million for the third quarter of fiscal 2025. Net Income The Company reported net income of $1.27 mil...